摘要
目的:探讨尤瑞克林治疗不同中国缺血性卒中分型(China ischemic stroke subclassification,CISS)急性脑梗死患者的临床疗效。方法:将汕头大学医学院第一附属医院神经内科2015年9月至2017年9月收治的268例急性脑梗死患者随机分为治疗组和对照组,每组134例。2组患者进行CISS分型。对照组患者给予常规治疗,治疗组患者在常规治疗基础上联用尤瑞克林,0.15PNA尤瑞克林溶于100mL生理盐水中静脉滴注,1次/d,持续治疗14d。在治疗前及治疗14d后分别对2组患者进行美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)评分及临床疗效评定。结果:2组患者治疗14d后,NIHSS评分比入院时均有下降,差异具有统计学意义(治疗组t=8.6,P<0.05;对照组t=8.79,P<0.05);其中治疗组患者的总有效率高于对照组,差异具有统计学意义(χ^2=9.46,P=0.002)。治疗组中仅大动脉粥样硬化型患者的NIHSS评分下降及总有效率与对照组差异有统计学意义(t=4.63,P<0.05;χ^2=6.90,P<0.05),其他亚型与对照组间差异无统计学意义(P>0.05)。结论:尤瑞克林能安全有效地改善大动脉粥样硬化型急性脑梗死患者的短期预后。
Objective:To investigate the clinical efficacy of urinary kallidinogenase in the treatment of acute cerebral infarction with different China ischemic stroke subclassification(CISS) types. Methods:268 patients with acute ischemic stroke admitted to the Department of Neurology,the First Affiliated Hospital of Medical College of Shantou University from September 2015 to September 2017 were randomly divided into treatment group and control group with 134 cases in each group. CISS typing was performed in both groups. The patients in the control group were given routine treatment only,while the patients in the treatment group were given urinary kallidinogenase on the basis of routine treatment. 0.15 PNA urinary kallidinogenase was dissolved in 100 mL saline by intravenous drip once a day for 14 days. NIHSS score and clinical efficacy were evaluated in both groups after admission and 14 days of treatment. Results:After 14 days of treatment,the NIHSS scores of the two groups were lower than those at admission,and the difference was statistically significant(t =8.6, P<0.05 in the treatment group;t =8.79, P<0.05 in the control group);the overall effective rate of the treatment group was higher significantly than that of the control group(χ^2 =9.46,P=0.002). In the treatment group, only the large artery atherosclerotic patients’NIHSS score decreased and the total effective rate of treatment was significantly different from that of the control group. There was no significant difference between the other subtypes in the treatment group and the control group. Conclusion: Urinary kallidinogenase can safely and effectively improve the short-term prognosis of patients with acute cerebral infarction of large artery atherosclerosis.
作者
陈思洽
郭毓武
王弘
吴少燕
陈朝琳
何文贞
CHEN Siqia;GUO Yuwu;WANG Hong;WU Shaoyan;CHEN Zhaolin;HEWenzhen(Department of Neurology,The First Affiliated Hospital of Shantou University Medical College,Shantou 515041,China;Department of Internal Medicine,Shanwei People's Hospital,Shanwei 516600,China)
出处
《汕头大学医学院学报》
2019年第2期92-95,共4页
Journal of Shantou University Medical College
基金
汕头市科技计划项目(汕府科[2016]19号)
关键词
尤瑞克林
急性脑梗死
CISS分型
动脉粥样硬化
urinary kallidinogenase
acute cerebral infarction
CISS types
atherosclerosis